Literature DB >> 21632682

The potential role of interferon-regulatory factor 7 among Taiwanese patients with systemic lupus erythematosus.

Li-Hsin Lin1, Pin Ling, Ming-Fei Liu.   

Abstract

OBJECTIVE: Type I interferons (IFN), especially IFN-α, have been proposed to underlie the pathogenesis of systemic lupus erythematosus (SLE). Members of the IFN regulatory factor (IRF) family, which regulate IFN expression, have been implicated as risk factors for SLE. Our aims were to investigate the expression of IRF7 and its correlation with disease activity and to explore the association in Taiwanese patients between 2 genetic single-nucleotide polymorphisms (SNP) of IRF7 and SLE.
METHODS: IRF7 messenger RNA (mRNA) levels were measured in peripheral blood mononuclear cells by real-time reverse transcription polymerase chain reaction in 51 adult patients with SLE and 65 age-matched and sex-matched controls. Their serum IFN-α levels were determined by ELISA and the clinical manifestations were recorded at the same time. Two IRF7 SNP, rs1061501 and rs1061502, were examined by genotyping across 92 patients with SLE and 92 age and sex-matched healthy control subjects.
RESULTS: Compared with controls, the expression of IRF7 mRNA was significantly increased in patients with SLE and was positively correlated with both the serum level of IFN-α and lupus disease activity. The distribution of SNP rs1061501 by genotype (CC, CT, and TT) and by allele (C, T) was significantly different between the SLE and the control group (p = 0.028 for genotype and p = 0.009 for allele). There were no significant differences for SNP rs1061502.
CONCLUSION: The results suggest that dysregulation of IRF7 might mediate an excessive production of IFN-α, which then exerts a crucial effect on the pathogenesis of human SLE. The IRF7 SNP rs1061501 TT genotype and T allele are enriched in Taiwanese patients with SLE and thus would seem to be associated with an increased risk of developing SLE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632682     DOI: 10.3899/jrheum.101004

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Interferon regulatory factor 3 as key element of the interferon signature in plasmacytoid dendritic cells from systemic lupus erythematosus patients: novel genetic associations in the Mexican mestizo population.

Authors:  K Santana-de Anda; D Gómez-Martín; A E Monsivais-Urenda; M Salgado-Bustamante; R González-Amaro; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

2.  Attenuation of interferon regulatory factor 7 activity in local infectious sites of trachea and lung for preventing the development of acute lung injury caused by influenza A virus.

Authors:  Lei Yang; Liqun Tu; Peiyan Zhao; Ying Wang; Shengnan Wang; Wenting Lu; Yangyang Wang; Xin Li; Yongli Yu; Shucheng Hua; Liying Wang
Journal:  Immunology       Date:  2019-02-27       Impact factor: 7.397

Review 3.  Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.

Authors:  Vince Kornél Grolmusz; Anikó Bozsik; János Papp; Attila Patócs
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

4.  Evaluation of the peripheral blood T and B cell subsets and IRF-7 variants in adult patients with severe influenza virus infection.

Authors:  Nursel Çalık Başaran; Çağman Tan; Lale Özışık; Begüm Özbek; Ahmet Çağkan İnkaya; Şehnaz Alp; Ebru Ortaç Ersoy; Deniz Çağdaş Ayvaz; İlhan Tezcan
Journal:  Health Sci Rep       Date:  2022-01-20

Review 5.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

6.  Two Genetic Variations in the IRF8 region are associated with Behçet's disease in Han Chinese.

Authors:  Yanni Jiang; Hong Wang; Hongsong Yu; Lin Li; Dengfeng Xu; Shengping Hou; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.